Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tetratherix Limited ( (AU:TTX) ) has issued an announcement.
BioOptix, Inc., a joint venture of Tetratherix Limited, has signed a development agreement with Alcon Research, LLC to advance its ophthalmic biomaterial solutions. This strategic partnership involves Alcon providing milestone-based funding to accelerate the commercialization of products derived from the Tetramatrix™ platform. The agreement is seen as a validation of Tetratherix’s technology, highlighting its commercial appeal to major players in the medical device industry.
The most recent analyst rating on (AU:TTX) stock is a Buy with a A$5.76 price target. To see the full list of analyst forecasts on Tetratherix Limited stock, see the AU:TTX Stock Forecast page.
More about Tetratherix Limited
Tetratherix Limited is a developer of novel clinical products based on its patented biomaterial platform technology. The company is involved in the ophthalmic biomaterials industry through its joint venture, BioOptix, which focuses on innovative ophthalmic biomaterial technologies.
Average Trading Volume: 10,787
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$102.5M
For detailed information about TTX stock, go to TipRanks’ Stock Analysis page.